22:03 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Auris misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) stock fell 49% Nov. 28 after the company said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
22:31 , Nov 28, 2017 |  BC Extra  |  Clinical News

Auris' lead candidate misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) fell $0.40 (49%) to $0.42 Tuesday after it said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
19:46 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Harmony raises $270M, licenses narcolepsy drug

On Oct. 6, CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an equity round from Valor Equity Partners, Fidelity Management & Research Co., HBM Healthcare Investments, Vivo Capital, venBio,...
22:53 , Oct 6, 2017 |  BC Extra  |  Financial News

Harmony raises $270M, licenses narcolepsy drug

CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an equity round from Valor Equity Partners, Fidelity Management & Research Co., HBM Healthcare Investments, Vivo Capital, venBio, Novo Holdings A/S...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Wakix pitolisant regulatory update

EMA’s CHMP recommended approval of Wakix pitolisant from Bioprojet to treat narcolepsy with or without cataplexy. The product is a histamine H3 receptor (HRH3) antagonist. Bioprojet Pharma S.a.r.l. , Paris, France   Product: Wakix pitolisant...
08:00 , Dec 8, 2014 |  BioCentury  |  Product Development

Verve for HERV

Servier could make its first foray into multiple sclerosis via an option deal with GeNeuro S.A. that it hopes will yield the first therapy targeted at a cause of the disease. Last week Servier agreed...
08:00 , Jan 23, 2014 |  BC Innovations  |  Tools & Techniques

Diagnosing narcolepsy

A new way to diagnose narcolepsy using T cells 1 has piqued the interest of at least two companies- Jazz Pharmaceuticals plc and GlaxoSmithKline plc . The former could use the results to help diagnose...
07:00 , Sep 30, 2013 |  BioCentury  |  Regulation

Wake-up call

Narcolepsy patients told FDA and companies at the agency's latest patient-focused drug development meeting they want a better balance of alertness and sleep. Specifically, this means better resolution of excessive daytime sleepiness - their worst...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

Ziarco, Pfizer deal

Newco Ziarco received exclusive, worldwide rights to develop and commercialize a portfolio of four assets from Pfizer for inflammatory and allergic diseases. Pfizer will receive an undisclosed equity stake in Ziarco and is eligible for...
08:00 , Nov 12, 2012 |  BioCentury  |  Finance

BVF's private return

Biotechnology Value Fund invested in a private company for the first time in more than five years, putting money into a spinout of potentially first-in-class assets from Pfizer Inc. (NYSE:PFE). Newco Ziarco Pharma Ltd. announced...